CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs
About this item
Full title
Author / Creator
Publisher
London: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
London: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
CD3‐T‐cell‐engager (TCE) therapies, such as bispecific T‐cell engagers (BiTEs), have achieved extraordinary success in treating hematological malignancies and have shown therapeutic effects comparable with those of chimeric antigen receptor (CAR)‐T therapies. However, solid tumors are challenging to treat with TCE therapies due to tumor heterogenei...
Alternative Titles
Full title
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_37c859c960f64b9e939b10e4985329f5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_37c859c960f64b9e939b10e4985329f5
Other Identifiers
ISSN
2769-643X
E-ISSN
2769-643X
DOI
10.1002/mba2.20
